Johnson & Johnson vs Payoneer Global Inc — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Johnson & Johnson is far larger — about 260.9× Payoneer Global Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| JNJ | PAYO | |
|---|---|---|
Market Cap | $626.09B | $2.40B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $7.17 |
52-Week Low | $172.78 | $4.27 |
Enterprise Value | $654.37B | $2.14B |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Payoneer (PAYO) trades at $7.07, down 0.28% on the day, with a bullish technical signal from moving averages and an oversold RSI. Revenue grew to $821.16M in 2025, but net income fell to $73.19M, and Q2 2026 earnings missed estimates. The company is set to be acquired by Nuvei for $7.40 per share, pending shareholder approval, amid legal scrutiny over deal fairness.
The outlook is acquisition-driven, with upside limited to the $7.40 buyout price unless a higher bid emerges. Risks include integration challenges, earnings volatility, and legal disputes. Analysts maintain a buy consensus with an $8.20 target, suggesting potential gains if the deal proceeds smoothly, but caution is warranted due to recent profit margin compression.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →